Matches in SemOpenAlex for { <https://semopenalex.org/work/W3123359267> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W3123359267 abstract "Abstract Background: Pembrolizumab is currently considered the standard second-line treatment for advanced urothelial carcinoma (UC). This study aimed to investigate the efficacy and safety of pembrolizumab in patients with advanced UC in real-world data, which is not well-reported. Methods: The study included 98 patients with advanced UC who were treated with pembrolizumab after platinum-based chemotherapy at eight hospitals. The efficacy, safety, and risk factors for prognosis were evaluated. Results: The median age was 73 years. Nineteen patients (19%) with performance status (PS) 2-4 were included. The percentages of liver, lung, bone, and lymph node metastasis were 18%, 27%, 19%, and 76%, respectively. The best response was complete response in nine patients (9%) and partial response in 16 patients (17%). The median progression-free survival and overall survival were 3.7 months (95% confidence interval [CI]: 2.8–4.7) and 11.8 months (95% CI: 6.7–17.0), respectively. Poor PS, liver metastasis, and higher C-reactive protein were poor prognostic factors. Hyperprogression was observed in nine patients (9%), who were mostly of poor PS and had high-volume lesions. Severe adverse events (AEs) were observed in 18 patients (19%), and five patients died because of AEs (5%). Atypical AEs, such as pneumocystis pneumonia and acute myeloid leukemia, were observed in our cohort. Conclusion: The efficacy of pembrolizumab for advanced UC in our cohort was better than a previous phase III trial (KEYNOTE-045), possibly owing to lower cancer volume and fewer visceral metastases in our patients." @default.
- W3123359267 created "2021-02-01" @default.
- W3123359267 creator A5014379308 @default.
- W3123359267 creator A5016134946 @default.
- W3123359267 creator A5024925008 @default.
- W3123359267 creator A5032171493 @default.
- W3123359267 creator A5033402086 @default.
- W3123359267 creator A5036460015 @default.
- W3123359267 creator A5036798489 @default.
- W3123359267 creator A5039868774 @default.
- W3123359267 creator A5047197138 @default.
- W3123359267 creator A5051605638 @default.
- W3123359267 creator A5052080757 @default.
- W3123359267 creator A5052920889 @default.
- W3123359267 creator A5056369807 @default.
- W3123359267 creator A5073333320 @default.
- W3123359267 creator A5089801704 @default.
- W3123359267 date "2020-11-03" @default.
- W3123359267 modified "2023-09-27" @default.
- W3123359267 title "Real-World Clinical Outcomes of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma" @default.
- W3123359267 doi "https://doi.org/10.21203/rs.3.rs-81346/v1" @default.
- W3123359267 hasPublicationYear "2020" @default.
- W3123359267 type Work @default.
- W3123359267 sameAs 3123359267 @default.
- W3123359267 citedByCount "0" @default.
- W3123359267 crossrefType "posted-content" @default.
- W3123359267 hasAuthorship W3123359267A5014379308 @default.
- W3123359267 hasAuthorship W3123359267A5016134946 @default.
- W3123359267 hasAuthorship W3123359267A5024925008 @default.
- W3123359267 hasAuthorship W3123359267A5032171493 @default.
- W3123359267 hasAuthorship W3123359267A5033402086 @default.
- W3123359267 hasAuthorship W3123359267A5036460015 @default.
- W3123359267 hasAuthorship W3123359267A5036798489 @default.
- W3123359267 hasAuthorship W3123359267A5039868774 @default.
- W3123359267 hasAuthorship W3123359267A5047197138 @default.
- W3123359267 hasAuthorship W3123359267A5051605638 @default.
- W3123359267 hasAuthorship W3123359267A5052080757 @default.
- W3123359267 hasAuthorship W3123359267A5052920889 @default.
- W3123359267 hasAuthorship W3123359267A5056369807 @default.
- W3123359267 hasAuthorship W3123359267A5073333320 @default.
- W3123359267 hasAuthorship W3123359267A5089801704 @default.
- W3123359267 hasBestOaLocation W31233592671 @default.
- W3123359267 hasConcept C121608353 @default.
- W3123359267 hasConcept C126322002 @default.
- W3123359267 hasConcept C143998085 @default.
- W3123359267 hasConcept C197934379 @default.
- W3123359267 hasConcept C2776256026 @default.
- W3123359267 hasConcept C2777701055 @default.
- W3123359267 hasConcept C2780057760 @default.
- W3123359267 hasConcept C2780352672 @default.
- W3123359267 hasConcept C2911057145 @default.
- W3123359267 hasConcept C3019882237 @default.
- W3123359267 hasConcept C71924100 @default.
- W3123359267 hasConcept C72563966 @default.
- W3123359267 hasConcept C90924648 @default.
- W3123359267 hasConceptScore W3123359267C121608353 @default.
- W3123359267 hasConceptScore W3123359267C126322002 @default.
- W3123359267 hasConceptScore W3123359267C143998085 @default.
- W3123359267 hasConceptScore W3123359267C197934379 @default.
- W3123359267 hasConceptScore W3123359267C2776256026 @default.
- W3123359267 hasConceptScore W3123359267C2777701055 @default.
- W3123359267 hasConceptScore W3123359267C2780057760 @default.
- W3123359267 hasConceptScore W3123359267C2780352672 @default.
- W3123359267 hasConceptScore W3123359267C2911057145 @default.
- W3123359267 hasConceptScore W3123359267C3019882237 @default.
- W3123359267 hasConceptScore W3123359267C71924100 @default.
- W3123359267 hasConceptScore W3123359267C72563966 @default.
- W3123359267 hasConceptScore W3123359267C90924648 @default.
- W3123359267 hasLocation W31233592671 @default.
- W3123359267 hasOpenAccess W3123359267 @default.
- W3123359267 hasPrimaryLocation W31233592671 @default.
- W3123359267 hasRelatedWork W2754795980 @default.
- W3123359267 hasRelatedWork W2772794544 @default.
- W3123359267 hasRelatedWork W2898071776 @default.
- W3123359267 hasRelatedWork W2904110710 @default.
- W3123359267 hasRelatedWork W2985344250 @default.
- W3123359267 hasRelatedWork W3033877262 @default.
- W3123359267 hasRelatedWork W3041652591 @default.
- W3123359267 hasRelatedWork W3175277114 @default.
- W3123359267 hasRelatedWork W3215044659 @default.
- W3123359267 hasRelatedWork W4353086468 @default.
- W3123359267 isParatext "false" @default.
- W3123359267 isRetracted "false" @default.
- W3123359267 magId "3123359267" @default.
- W3123359267 workType "article" @default.